Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176172 · ClinicalTrials.gov registry record · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
A Phase 3 study of Nicotine Dependence and HIV/AIDS, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
- 2
- Study locations
NCT04176172 is a Phase 3 study of Nicotine Dependence and HIV/AIDS that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 340 participants, above the 182-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (87% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04176172, a Phase 3 study of Nicotine Dependence and HIV/AIDS, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
- 2
- Study locations
Study Summary
The advent of anti-retroviral therapy (ART) for people living with HIV/AIDS (PLWHA) substantially improved life expectancy but has also led to the critical need to address modifiable risk factors associated with cancer and cardiovascular disease, such as tobacco smoking. HIV-infected smokers lose more life-years due to tobacco use than they do to their HIV infection. There have been relatively few studies of tobacco use treatments for PLWHA and systematic reviews show that there are insufficient data to conclude that tobacco dependence interventions that are efficacious in the general population are efficacious for PLWHA. Further, many studies in this area have lacked randomization and a control group, infrequently used an intent-to-treat (ITT) approach and biological verification of tobacco abstinence, and lacked post-treatment follow-up.10 What investigators do know thus far is that behavioral interventions and the nicotine patch yield moderate effects on cessation; and 2 recent placebo-controlled trials - one in France and one by this lab - found that varenicline is safe and effective for treating tobacco use among PLWHA, but yield quit rates that are substantially lower than those reported in the general population. Thus, there is a critical need to rigorously test novel ways to optimize tobacco cessation treatment for smokers with HIV.
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Nicotine patch
- BEHAVIORAL Standard treatment
- BEHAVIORAL Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Study Locations (2)
Illinois
- Northwestern University - Chicago
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04176172
The ClinicalTrials.gov registry entry for NCT04176172 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 182-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (87% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Nicotine Dependence appearing as the primary indexed condition, and to 4 interventions - of which Varenicline is the first listed.
NCT04176172 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04176172 about?
NCT04176172 is a clinical study titled "Optimizing Tobacco Use Treatment for PLWHA". The advent of anti-retroviral therapy (ART) for people living with HIV/AIDS (PLWHA) substantially improved life expectancy but has also led to the critical need to address modifiable risk factors associated with cancer and cardiovascular disease, such as tobacco smoking. HIV-infected smokers lose mo...
What is the current status of trial NCT04176172?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2020-02-17. Estimated completion is 2026-08-31.
What conditions does trial NCT04176172 study?
This clinical trial studies the following conditions: Nicotine Dependence, HIV/AIDS.
What interventions are being tested in trial NCT04176172?
The interventions under investigation include: Varenicline (DRUG), Nicotine patch (DRUG), Standard treatment (BEHAVIORAL), Standard treatment + Managed Problem Solving (MAPS) adherence intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04176172?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04176172 being conducted?
This trial has 2 study locations across Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.
RECRUITING · Phase 3
-
Smoking Treatment in HIV Clinical Care Settings
COMPLETED · Phase 3
-
Bupropion Treatment for Youth Smoking Cessation
COMPLETED · Phase 3
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.